Tezspire Just Crashed Dupixent's Party in a Big Way

Why "Upstream" Is the Magic Word

To understand why Tezspire might be different, you need a quick lesson in inflammatory plumbing.

Think of allergic inflammation like a river system. Downstream, you have individual tributaries: IL-4, IL-5, IL-13 (these are cytokines, the chemical messengers that drive inflammation). Most biologics, including Dupixent, target one or two of those tributaries. They work well, but some water still gets through.

Tezspire goes after the source of the river. It blocks TSLP, a protein released by epithelial cells (the cells lining your airways, sinuses, and esophagus) in response to allergens, viruses, and pollutants. TSLP sits at the very top of the inflammatory cascade. Block it, and you cut off multiple downstream pathways at once.

It's the difference between plugging individual leaks and turning off the faucet. At least, that's the theory. And the CROSSING results suggest the theory holds up in EoE.

The Trial, by the Numbers

CROSSING enrolled 368 patients aged 12 to 80 with symptomatic and histologically active EoE. It was randomized, double-blind, and placebo-controlled: the gold standard design.

The study tested two doses of Tezspire, and both worked. The co-primary endpoints were histologic remission (whether the eosinophil invasion in the esophagus actually reversed under a microscope) and improvement in dysphagia (the frequency and severity of swallowing problems). Tezspire beat placebo on both counts.

Perhaps more importantly, the benefits didn't fade. Results at week 24 held steady through the full 52-week treatment period. That durability matters in a chronic disease where patients need lifelong management. The safety profile looked consistent with what doctors already know from Tezspire's other approved uses, though the prescribing information does note a risk of hypersensitivity reactions, including rare cases of anaphylaxis.

The Commercial Chess Match

For AstraZeneca and Amgen, these results are a franchise-building moment. Tezspire already competes in the crowded severe asthma market and won its CRSwNP approval in 2025. Adding EoE would create a three-indication biologic spanning the major epithelial-driven allergic diseases.

That's a powerful story for two reasons. First, it validates the upstream TSLP mechanism across multiple organs: lungs, sinuses, esophagus. Second, it gives sales reps a broader narrative when talking to allergists and gastroenterologists. One drug, three conditions, one underlying biology.

For Dupixent, the arrival of real competition is uncomfortable but not catastrophic. Sanofi's blockbuster still has a massive head start, a broader age range (approved down to age 1 in EoE), and years of real-world prescribing data. But monopolies don't last forever, and doctors love having options, especially for patients who aren't responding to first-line biologics.

The key questions now are regulatory timing and positioning. How quickly will AstraZeneca and Amgen file for the EoE indication? Will payers treat Tezspire as a first-line biologic option or reserve it for Dupixent failures? And will the "upstream" mechanism translate into a clinical differentiation story that moves market share?

The Bigger Picture

Zoom out and there's something elegant happening here. The biotech industry spent years going after individual cytokines, one target at a time. Tezspire's expanding resume suggests that going upstream, targeting the alarm signals that epithelial cells send out before the full inflammatory cascade begins, might be a more versatile strategy.

That doesn't mean TSLP inhibition will work everywhere. Biology is messy, and plenty of upstream targets have failed to deliver on their theoretical promise. But three positive Phase III programs across three different organs is a pretty strong vote of confidence.

For the roughly half a million Americans with EoE, the calculus is simpler. More options are better. And a drug that attacks the root of the problem, rather than pruning individual branches, is exactly the kind of option worth getting excited about.

The $795M Bet on a Brain Channel That Already Failed Once

SK Biopharmaceuticals just paid $795 million for a drug that targets the same brain channel class that flopped a decade ago. The early data on opakalim suggests the second-generation version might actually be worth it.